Skip to main content

Advertisement

SpringerLink
Log in

Bridging the Pharmacokinetics and Pharmacodynamics of UK-279,276 Across Healthy Volunteers and Stroke Patients Using a Mechanistically Based Model for Target-Mediated Disposition

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Purpose

UK-279,276 is a recombinant glycoprotein and is a selective antagonist of CD11b, which in preclinical models of acute stroke blocks the infiltration of activated neutrophils into the site of infarction. Binding of UK-279,276 to the CD11b receptors is hypothesized to facilitate its elimination. The event of an acute stroke leads to proliferation of neutrophils and an up-regulation of CD11b, which results in different pharmacokinetics/pharmacodynamics (PK/PD) in patients than in healthy volunteers. The aim of this current analysis was to develop a mechanistically based model to bridge the differences between healthy volunteers and patients.

Methods

PK samples, neutrophil counts, and total number and number of free CD11b receptors per neutrophils from three healthy volunteer studies (n = 98) and one patient study (n = 169) were modeled using the mixed effects modeling software NONMEM version VI (beta). Three mechanistic submodels were developed based on underlying physiology and pharmacology: (1) neutrophil maturation and proliferation, (2) CD11b up-regulation, and (3) three clearance pathways for UK-279-276 including CD11b-mediated elimination.

Results

The model accurately described the time course of CD11b expression, CD11b binding, and the measured PK of UK-279,276 and accounted for the PK/PD differences between healthy volunteers and patients.

Conclusions

A complex mechanistic model that closely resembled the “true” underlying system provided an effective bridge between healthy volunteers and patients by appropriately accounting for the underlying disease-dependent target mediated disposition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Abbreviations

PD:

pharmacodynamics

PK:

pharmacokinetics

References

  1. N. Jiang M. Chopp S. Chahwala (1998) ArticleTitleNeutrophil inhibitory factor treatment of focal cerebral ischemia in the rat Brain Res. 788 25–34 Occurrence Handle10.1016/S0006-8993(97)01503-5 Occurrence Handle9554941

    Article  PubMed  Google Scholar 

  2. M. Moyle D. L. Foster D. E. McGrath S. M. Brown Y. Laroche J. Meutter ParticleDe P. Stanssens C. A. Bogowitz V. A. Fried J. A. Ely et al. (1994) ArticleTitleA hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18 J.Biol. Chem. 269 10008–10015 Occurrence Handle7908286

    PubMed  Google Scholar 

  3. R. L. Engler G. W. Schmid-Schonbein R. S. Pavelec (1983) ArticleTitleLeukocyte capillary plugging in myocardial ischemia and reperfusion in the dog Am. J. Pathol. 111 98–111 Occurrence Handle6837725

    PubMed  Google Scholar 

  4. M. C. Mazzoni G. W. Schmid-Schonbein (1996) ArticleTitleMechanisms and consequences of cell activation in the microcirculation Cardiovasc. Res. 32 709–719 Occurrence Handle10.1016/0008-6363(96)00146-0 Occurrence Handle8915189

    Article  PubMed  Google Scholar 

  5. S. J. Weiss (1989) ArticleTitleTissue destruction by neutrophils N. Engl. J. Med. 320 365–376 Occurrence Handle2536474

    PubMed  Google Scholar 

  6. M. Krams K. R. Lees W. Hacke A. P. Grieve J. M. Orgogozo G. A. Ford (2003) ArticleTitleAcute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke Stroke 34 2543–2548 Occurrence Handle10.1161/01.STR.0000092527.33910.89 Occurrence Handle14563972

    Article  PubMed  Google Scholar 

  7. M. E. Sughrue E. S. Connolly SuffixJr (2004) ArticleTitleEffectively bridging the preclinical/clinical gap: the results of the ASTIN trial Stroke 35 e81–e82 Occurrence Handle10.1161/01.STR.0000121164.29117.44 Occurrence Handle14988564

    Article  PubMed  Google Scholar 

  8. K. R. Lees H. C. Diener K. Asplund M. Krams (2003) ArticleTitleUK-279-276, a neutriphil inhibitory glycoprotein, in acute stroke Stroke 34 1704–1709 Occurrence Handle10.1161/01.STR.0000078563.72650.61 Occurrence Handle12805489

    Article  PubMed  Google Scholar 

  9. S. L. Beal L. B. Sheiner (1998) NONMEM Users Guide, NONMEM Project Group University of California San Francisco

    Google Scholar 

  10. E. N. Jonsson M. O. Karlsson (1999) ArticleTitleXpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput. Methods Programs Biomed. 58 51–64 Occurrence Handle10.1016/S0169-2607(98)00067-4 Occurrence Handle10195646

    Article  PubMed  Google Scholar 

  11. U. Wahlby E. N. Jonsson M. O. Karlsson (2001) ArticleTitleAssessment of actual significance levels for covariate effects in NONMEM J. Pharmacokinet. Pharmacodyn. 28 231–252 Occurrence Handle10.1023/A:1011527125570 Occurrence Handle11468939

    Article  PubMed  Google Scholar 

  12. U. Wahlby M. R. Bouw E. N. Jonsson M. O. Karlsson (2002) ArticleTitleAssessment of type I error rates for the statistical sub-model in NONMEM J. Pharmacokinet. Pharmacodyn. 29 251–269 Occurrence Handle10.1023/A:1020254823597 Occurrence Handle12449498

    Article  PubMed  Google Scholar 

  13. H. Kato K. Kogure X. H. Liu T. Araki Y. Itoyama (1996) ArticleTitleProgressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat Brain Res. 734 203–212 Occurrence Handle10.1016/0006-8993(96)00636-1 Occurrence Handle8896826

    Article  PubMed  Google Scholar 

  14. R. Webster J. Phipps R. Hyland D. Walker (2003) ArticleTitleEvaluation of the role of the asialoglycoprotein receptor in the clearance of UK-279,276 (recombinant neutrophil inhibitory factor) Xenobiotica 33 945–956 Occurrence Handle10.1080/00498250310001614295 Occurrence Handle14514443

    Article  PubMed  Google Scholar 

  15. L. E. Friberg A. Henningsson H. Maas L. Nguyen M. O. Karlsson (2002) ArticleTitleModel of chemotherapy-induced myelosuppression with parameter consistency across drugs J. Clin. Oncol. 20 4713–4721 Occurrence Handle10.1200/JCO.2002.02.140 Occurrence Handle12488418

    Article  PubMed  Google Scholar 

  16. R. I. Walker R. Willemze (1980) ArticleTitleNeutrophil kinetics and the regulation of granulopoiesis Rev. Infect. Dis. 2 282–292 Occurrence Handle6994209

    PubMed  Google Scholar 

  17. S. Marshall, F. Macintyre, I. James, M. Krams, and E. N. Jonsson. Application of a mechanistically based pharmacokinetic/pharmacodynamic model in the development of neutrophil inhibitory factor UK-279,276 for the treatment of ischaemic stroke. Accepted for publication in Clin Pharmacokinet (2005).

  18. D. E. Mager W. J. Jusko (2001) ArticleTitleGeneral pharmacokinetic model for drugs exhibiting target-mediated drug disposition J. Pharmacokinet. Pharmacodyn. 28 507–532 Occurrence Handle10.1023/A:1014414520282 Occurrence Handle11999290

    Article  PubMed  Google Scholar 

  19. G. Levy (1994) ArticleTitlePharmacologic target-mediated drug disposition Clin. Pharmacol. Ther. 56 248–252 Occurrence Handle7924119

    PubMed  Google Scholar 

  20. J. D. Bowen S .H. Petersdorf T. L. Richards K. R. Maravilla D. C. Dale T. H. Price T. P. St John A. S. Yu (1998) ArticleTitlePhase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis Clin. Pharmacol. Ther. 64 339–346 Occurrence Handle10.1016/S0009-9236(98)90183-7 Occurrence Handle9757158

    Article  PubMed  Google Scholar 

  21. R. J. Bauer R. L. Dedrick M. L. White M. J. Murray M.R. Garovoy (1999) ArticleTitlePopulation pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis J. Pharmacokinet. Biopharm. 27 397–420 Occurrence Handle10.1023/A:1020917122093 Occurrence Handle10826130

    Article  PubMed  Google Scholar 

  22. E. N. Jonsson M. O. Karlsson (1998) ArticleTitleAutomated covariate model building within NONMEM Pharm. Res. 15 1463–1468 Occurrence Handle10.1023/A:1011970125687 Occurrence Handle9755901

    Article  PubMed  Google Scholar 

  23. J. W. Mandema D. Verotta L. B. Sheiner (1992) ArticleTitleBuilding population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects J. Pharmacokinet. Biopharm. 20 511–528 Occurrence Handle10.1007/BF01061469 Occurrence Handle1287200

    Article  PubMed  Google Scholar 

  24. L. Zhang Z. G. Zhang R. L. Zhang M. Lu M. Krams M. Chopp (2003) ArticleTitleEffects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke Stroke 34 1790–1795 Occurrence Handle10.1161/01.STR.0000077016.55891.2E Occurrence Handle12805500

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacokinetics & Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE-751 24, Uppsala, Sweden

    E. Niclas Jonsson

  2. Department of Clinical Pharmacology, Pfizer Global Research & Development, Sandwich, UK

    Fiona Macintyre, Ian James & Scott Marshall

  3. Department of Experimental Medicine, Pfizer Global Research & Development, Groton, Connecticut, 06340, USA

    Michael Krams

Authors
  1. E. Niclas Jonsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fiona Macintyre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian James
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Krams
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Scott Marshall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Niclas Jonsson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jonsson, E.N., Macintyre, F., James, I. et al. Bridging the Pharmacokinetics and Pharmacodynamics of UK-279,276 Across Healthy Volunteers and Stroke Patients Using a Mechanistically Based Model for Target-Mediated Disposition. Pharm Res 22, 1236–1246 (2005). https://doi.org/10.1007/s11095-005-5264-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-005-5264-x

Key Words

Search

Navigation